We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
–
Cap. Flow
+$108M
Cap. Flow %
89.86%
Top 10 Hldgs %
99.9%
Holding
11
New
11
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$49.7M
2
ANIK icon
Anika Therapeutics
ANIK
+$16.8M
3
EOLS icon
Evolus
EOLS
+$13.5M
4
LAB icon
Standard BioTools
LAB
+$10.6M
5
ADMA icon
ADMA Biologics
ADMA
+$8.25M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.11B
$58.9M 49%
+9,243,627
New +$49.7M
ANIK icon
2
Anika Therapeutics
ANIK
$203M
$17.5M 14.58%
+591,675
New +$16.8M
EOLS icon
3
Evolus
EOLS
$377M
$13.1M 10.88%
+1,740,700
New +$13.5M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$10.4M 8.64%
+2,676,093
New +$8.25M
LAB icon
5
Standard BioTools
LAB
$350M
$10M 8.35%
+8,576,799
New +$10.6M
VRNA
6
DELISTED
Verona Pharma
VRNA
$4.78M 3.98%
+183,064
New +$2.44M
SCTL
7
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2.39M 1.99%
+1,603,214
New +$2.52M
EYPT icon
8
EyePoint Inc
EYPT
$1.12B
$1.52M 1.27%
+435,298
New +$1.92M
ALIM
9
DELISTED
Alimera Sciences
ALIM
$1.3M 1.08%
+478,777
New +$2.04M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.5B
$159K 0.13%
+1,000
New +$147K
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$122K 0.1%
+4,333
New +$122K

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q4 2022 Portfolio in Review

Q4 2022 is the first quarter with a 13F filing on record for Caligan Partners, which disclosed 11 positions worth $120M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Liquidia Corp: 9,243,627 shares worth $58.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Caligan Partners's largest Q4 2022 buy was Liquidia Corp: 9,243,627 shares worth $58.9M.
  • Caligan Partners's ten largest holdings make up 100% of its $120M portfolio in Q4 2022.
  • Caligan Partners disclosed 11 positions in Q4 2022, its first 13F filing on record.

Based on Caligan Partners's 13F filing for Q4 2022, filed 15 Feb 2023.